Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
1 March 2018
E-001311-18
Question for written answer
to the Commission
Rule 130
Roberta Metsola (PPE)

 Subject:  Health technology assessment

Health technology assessment (HTA) measures the added value of new health technologies (i.e. medicinal products, medical equipment and diagnostic and treatment methods) compared with existing ones.

Can the Commission specify whether its upcoming proposal on HTA will focus on the issue of having multiple national assessments for the same products that sometimes produce different results for patients and industry?

Last updated: 13 March 2018Legal notice